Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Chevron Says Damage at Wheatstone LNG Will Hamper Restart - 2Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- 3Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- 4Ways to track down the Right Criminal Legal counselor
- 5I’m a neuroscientist who taught rats to drive − their joy suggests how anticipating fun can enrich human life
- What is a Trump Gold Card? U.S. launches $1 million immigration visas
- ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- Compassion and Association: Building Significant Connections
- Real time features for Films and Programs
- Katz alleges Army Radio workers misled High Court in bid to halt closure
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
- Vote In favor of Your Favored Treat
